Gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein. In order to insert new genes directly into cells, a vehicle called a “vector” is used which is genetically engineered to deliver the gene.
The global gene therapy market is mainly driven by rising prevalence of various chronic diseases such as cancer & rare genetic disorders, robust pipeline, and growing government initiatives. Furthermore, increasing investment for R&D activities to launch more effective therapy is also playing a pivotal role in contributing to the market growth globally. However, high cost of therapy is likely to hinder the market growth to a certain extent.
The global gene therapy market has been analyzed from four main perspectives: Vector Type, Delivery Method, Disease Indication and Region.
Based on vector type, the gene therapy market has been segmented into viral vector and non-viral vector. The viral vector segment is further categorized into adenovirus, retrovirus, lentivirus, adeno-associated virus, herpes simplex virus and others (poxvirus, vaccinia virus, etc.). Whereas, non-viral vector is further categorized into naked DNA, transfection, liposomes, nanoparticles and others (nucleofection, transposons, etc.). The non-viral vector segment is expected to be fastest growing segment during the forecast period owing to its advantages over viral vector. Non-viral vectors are safer, cheaper, more reproducible and do not present DNA size limit.
Based on delivery method, the gene therapy market has been segmented into in vivo gene therapy and ex vivo gene therapy. Ex vivo gene therapy refers to the process of genetically altering a person’s cells outside of the body and then transplanting them back in. Whereas, In vivo gene therapy refers to direct administration either intravenously, known as systemic administration, or locally to a specific organ of interest. The ex vivo gene therapy segment holds the largest share in the market. The growth of the segment can be attributed to its wide application in hematopoietic stem cells (HSCs), which are relevant to blood & immunological diseases and genetic diseases that affect tissues and organs easily accessible by blood cells.
Based on disease indication, the gene therapy market has been segmented into cancer, neurological diseases, rare diseases, cardiovascular diseases and others (infectious diseases, hepatological diseases, etc.). The cancer segment accounted for the largest share in the market. The growth of the segment can be attributed to the rising prevalence of different types of cancer all over the world coupled with the approval of different types of gene therapy for the treatment of cancer. Furthermore, presence of large number of gene therapy candidates in pipeline is also expected to boost the growth of the market in the forecast period.
Based on region, the global gene therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the gene therapy market, followed by Asia Pacific. The large share of North America in the global market can largely be attributed to the advanced healthcare infrastructure, presence of prominent players, rising prevalence of cancer in the region, rising investments in the R&D of gene therapy and robust therapy pipeline.
The gene therapy market is marked by presence of prominent players such Novartis AG, Amgen Inc., Gilead Sciences, Inc., Bayer AG, REGENXBIO Inc., uniQure N.V., Voyager Therapeutics, Spark Therapeutics, Inc., SIBIONO, and Orchard Therapeutics plc. Other players operating in the market are bluebird bio, Inc., Audentes Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, among others.
|Market Size Period||2018-2031|
|Market Segments||Asessment of Gene Therapy Market By:
• Vector Type
• Delivery Method
• Disease Indication
|Geographic Scope||• North America
◦ Rest of Europe (RoE)
• Asia Pacific
◦ Rest of Asia Pacific (RoAPAC)
• Rest of the World
◦ Latin America
◦ Middle East & Africa
|Companies Covered||Novartis AG, Amgen Inc., Gilead Sciences, Inc., Bayer AG, REGENXBIO Inc., uniQure N.V., Voyager Therapeutics, Spark Therapeutics, Inc., SIBIONO, and Orchard Therapeutics plc., bluebird bio, Inc., Audentes Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, among others.|
1 RESEARCH ENVELOPE
1.1 Market Classification
1.2 Scope of the Study
1.2.1 Timeline Considered for Market Study
· Historic Years – 2018 & 2019
· Base Year – 2020
· Projected Years – 2021 to 2031
1.3 Currency Used in the Report
2 RESEARCH METHODOLOGY
2.1 Research Approach
2.2 Data Collection Methodology
2.3 Data Sources
2.3.1 Secondary Sources
2.3.2 Primary Sources
2.4 Market Crackdown Methodology
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Data Forecasting Model
2.6 Limitations and Assumptions for Study
3 HEADWINDS & TAILWINDS ASSESSMENT
4 MARKET OPPORTUNITIES ASSESSMENT
5 PREMIUM INSIGHTS
5.1 Key Market Trends
5.2 Key Players & Their Competitive Positioning (2020)
5.3 COVID-19 Impact Assessment
5.4 Pipeline Assessment
6 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY VECTOR TYPE
6.1 Viral Vector
6.1.4 Adeno-Associated Virus
6.1.5 Herpes Simplex Virus
6.1.6 Others (Poxvirus, Vaccinia Virus, Etc.)
6.2 Non-Viral Vector
6.2.1 Naked DNA
6.2.5 Others (Nucleofection, Transposons, Etc.)
7 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY DELIVERY METHOD
7.1 In Vivo Gene Therapy
7.2 Ex Vivo Gene Therapy
8 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY DISEASE INDICATION
8.2 Neurological Diseases
8.3 Rare Diseases
8.4 Cardiovascular Diseases
8.5 Others (Infectious Diseases, Hepatological Diseases, Etc.)
9 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY REGION
9.1 North America Gene Therapy Market
9.1.1 North America Gene Therapy Market, By Country
9.1.2 North America Gene Therapy Market, By Vector Type
9.1.3 North America Gene Therapy Market, By Delivery Method
9.1.4 North America Gene Therapy Market, By Disease Indication
9.2 Europe Gene Therapy Market
9.2.1 Europe Gene Therapy Market, By Country/Region
188.8.131.52 Rest of Europe (ROE)
9.2.2 Europe Gene Therapy Market, By Vector Type
9.2.3 Europe Gene Therapy Market, By Delivery Method
9.2.4 Europe Gene Therapy Market, By Disease Indication
9.3 Asia Pacific Gene Therapy Market
9.3.1 Asia Pacific Gene Therapy Market, By Country/Region
184.108.40.206 Rest of Asia Pacific (RoAPAC)
9.3.2 Asia Pacific Gene Therapy Market, By Vector Type
9.3.3 Asia Pacific Gene Therapy Market, By Delivery Method
9.3.4 Asia Pacific Gene Therapy Market, By Disease Indication
9.4 Rest of the World (RoW) Gene Therapy Market
9.4.1 Rest of the World Gene Therapy Market, By Region
220.127.116.11 Latin America
18.104.22.168 Middle East & Africa
9.4.2 Rest of The World Gene Therapy Market, By Vector Type
9.4.3 Rest of The World Gene Therapy Market, By Delivery Method
9.4.4 Rest of The World Gene Therapy Market, By Disease Indication
10 COMPANY PROFILES
10.1 Novartis AG
10.1.1 Business Overview
10.1.2 Financial Metrics*
10.1.3 Product Portfolio
10.1.4 Key Developments
10.2 Amgen Inc.
10.3 Gilead Sciences, Inc.
10.4 Bayer AG
10.5 REGENXBIO Inc.
10.6 uniQure N.V.
10.7 Voyager Therapeutics
10.8 Spark Therapeutics, Inc.
10.10 Orchard Therapeutics plc
*Insights on financial metrics is subject to availability of information in the public domain
3D printing also known as additive manufacturing is a process of making three dimensional solid objects from a CAD model or a digital 3D model. The term "3D printing" can refer to a variety of proc...
Hemophilia is a rare inherited bleeding disorder in which the blood does not clot properly which leads to spontaneous bleeding as well as bleeding following injuries or surgery. Blood contains prot...
The term halal is particularly associated with Islamic dietary laws and especially meat processed & prepared in accordance with those requirements. Halal is an Arabic word that means permissible. H...
Urinalysis is a test & analysis of urine to detect and manage a wide range of disorders, namely urinary tract infections, kidney disease and diabetes, among others. It includes a group of physical,...
Allergy is an exaggerated reaction by the immune system in response to exposure to certain foreign substances. These foreign substances are called as allergens and includes pollens, dust mites, mol...
Micro-catheters are a broad term, often used to describe thin wall, small diameter catheters and delivery devices used in minimally invasive applications. Its small build makes it ideal for navigat...
Remote patient monitoring (RPM) is a subset of telehealth. It is a technology that enables monitoring of patients outside of conventional clinical settings.
Femtech is a term applied to a category of software, diagnostics, products and services that focus on women's health.
Telehealth is a broader array of digital healthcare activities & services and can be defined as distribution of health-related services & information including medical care, provider & patient educ...
Sleep apnea is a condition where breathing is interrupted during sleep. It is considered a serious sleep disorder in which breathing repeatedly stops and starts.
A MedTech CDMO is a company that serves other companies in the medical device industry on contract basis and provides comprehensive services ranging from design & development, prototyping, tooling,...
Wearable medical devices are electronic devices that are designed to collect the data of users' personal health and exercise. It offers a convenient means of monitoring many physiological features,...
A contract research organization (CRO) also known as a clinical research organization, is an organization that provides services to pharmaceutical, biotechnology, and medical device companies.
Cell and gene therapy (CGT) companies partner with CGT CDMOs to get support on discovery, preclinical, clinical stages, CGT product development, manufacturing, and commercial manufacturing.
Contract Research, Development and Manufacturing (CRDMO) provides a fully integrated suite of end-to-end solutions for discovery, development, and manufacturing to meet all future market demands.